Find Clinical Trials

All CategoriesMedications / Interventions»Ff»Fludarabine Monophosphate



Join Paid Clinical Trials



  • Condition:   Recurrent Head and Neck Cancer
    Interventions:   Biological: Ad/PNP;   Drug: Fludarabine Phosphate
    Sponsors:   PNP Therapeutics, Inc.;   Food and Drug Administration (FDA);   Stanford University;   Emory University
    Recruiting

  • Conditions:   Myeloid Malignancies;   Acute Myelogenous Leukemia;   Chronic Myelogenous Leukemia;   Myeloproliferative Disorders;   Myelodysplastic Syndrome
    Interventions:   Drug: Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose);   Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
    Sponsor:   Hackensack Meridian Health
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Myeloid Leukemia;   Acute Lymphatic Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine;   Radiation: Total Marrow Irradiation (TMI)
    Sponsors:   Naoyuki G. Saito, M.D., Ph.D.;   Indiana University
    Recruiting

  • Conditions:   Sickle Cell Disease;   Sickle Cell Anemia;   SCD
    Interventions:   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplant (HSCT)
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Melphalan;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Keratinocyte Growth Factor (KGF)
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Conditions:   Hematopoietic Neoplasms;   Tumors of B Cells;   B-cell Surface Antigens CD19, CD20 and CD23;   T-cell Antigen CD5;   B-cell Receptor (BCR)
    Interventions:   Drug: Ibrutinib;   Drug: Fludarabine
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Chronic Myelomonocytic Leukemia (CMML);   MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable);   Hematopoietic Stem Cell Transplant
    Interventions:   Drug: Venetoclax;   Drug: Fludarabine;   Drug: Busulfan
    Sponsor:   Jacqueline Garcia, MD
    Recruiting

  • Condition:   Adult Lymphoblastic Lymphoma
    Interventions:   Drug: Fludarabine;   Procedure: Total Body Irradiation
    Sponsor:   University of Alabama at Birmingham
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Genetic: GINAKIT Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital
    Recruiting

  • Condition:   Bone Marrow Failure Syndromes
    Interventions:   Other: MRD-BMT with Fludarabine-based RIC for Acquired AA;   Other: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia;   Other: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Secondary Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Radiation: Total Marrow Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematological Malignancy Undergoing a Related Donor Haploidentical HCT;   Leukemia;   Multiple Myeloma;   Lymphoma
    Interventions:   Drug: Evomela;   Drug: Fludarabine;   Radiation: Total Body Irradiation
    Sponsor:   Medical College of Wisconsin
    Recruiting

  • Condition:   Liver Cancer Pediatric
    Interventions:   Genetic: GAP T cells;   Drug: Cytoxan;   Drug: Fludara
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   Cancer Prevention Research Institute of Texas;   V Foundation;   Cookies for Kids' Cancer Foundation;   Curing Kids' Cancer Foundation
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplantation;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Night Sweats for More Than 1 Month Without Evidence of Infection;   Progressive Marrow Failure;   Weight Loss of 10% or More Within the Previous 6 Months;   Fevers Higher Than 100.5 Degress F or 38.0 Degrees C for 2 or More Weeks
    Interventions:   Drug: Ibrutinib;   Drug: Fludarabine;   Drug: Pembrolizumab
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: CAR-T Cells
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia With FLT3/ITD Mutation;   Acute Myeloid Leukemia With Gene Mutations;   Aplastic Anemia;   B-Cell Non-Hodgkin Lymphoma;   CD40 Ligand Deficiency;   Chronic Granulomatous Disease;   Chronic Leukemia in Remission;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Congenital Amegakaryocytic Thrombocytopenia;   Congenital Neutropenia;   Congenital Pure Red Cell Aplasia;   Glanzmann Thrombasthenia;   Immunodeficiency Syndrome;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Paroxysmal Nocturnal Hemoglobinuria;   Plasma Cell Myeloma;   Polycythemia Vera;   Recurrent Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndrome;   Severe Aplastic Anemia;   Shwachman-Diamond Syndrome;   Sickle Cell Disease;   T-Cell Non-Hodgkin Lymphoma;   Thalassemia;   Waldenstrom Macroglobulinemia;   Wiskott-Aldrich Syndrome
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Sorafenib;   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Filgrastim;   Drug: Mycophenolate mofetil
    Sponsors:   M.D. Anderson Cancer Center;   Bayer
    Recruiting

  • Condition:   Sarcoma
    Interventions:   Genetic: Autologous HER2-specific T cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Conditions:   Relapsed Neuroblastoma;   Refractory Neuroblastoma
    Interventions:   Genetic: C7R-GD2.CART cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Not yet recruiting

  • Conditions:   T-cell Acute Lymphoblastic Leukemia;   T-cell Acute Lymphoblastic Lymphoma;   T-non-Hodgkin Lymphoma
    Interventions:   Genetic: CD7.CAR/28zeta CAR T cells;   Drug: Fludarabine;   Drug: Cytoxan
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Drug: ATG;   Radiation: Total Marrow Irradiation;   Procedure: Stem Cell Product Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsor:   University of Illinois at Chicago
    Recruiting

  • Conditions:   Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11;   Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1;   de Novo Myelodysplastic Syndrome;   High Risk Myelodysplastic Syndrome;   Inv(16);   Myelodysplastic Syndrome With Excess Blasts;   t(16;16);   t(8;21);   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Drug: Decitabine;   Biological: Filgrastim-sndz;   Drug: Fludarabine Phosphate;   Drug: Gemtuzumab Ozogamicin;   Drug: Idarubicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Small Lymphocytic Lymphoma;   Relapsed Adult ALL;   Relapsed CLL;   Relapsed Non Hodgkin Lymphoma
    Interventions:   Genetic: CD19.CAR-aNKT cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Not yet recruiting

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Procedure: T Cell Infusion
    Sponsors:   M.D. Anderson Cancer Center;   Ziopharm;   Intrexon Corporation
    Recruiting

  • Conditions:   T-cell Acute Lymphoblastic Lymphoma;   T-non-Hodgkin Lymphoma;   T-cell Acute Lymphoblastic Leukemia
    Interventions:   Genetic: CD5.CAR/28zeta CAR T cells;   Drug: Fludarabine;   Drug: Cytoxan
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting

  • Conditions:   Anemia;   ASXL1 Gene Mutation;   EZH2 Gene Mutation;   IDH1 Gene Mutation;   IDH2 Gene Mutation;   Plasma Cell Myeloma;   Primary Myelofibrosis;   Recurrent Plasma Cell Myeloma;   Secondary Myelofibrosis;   Thrombocytopenia
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis
    Sponsor:   University of Utah
    Recruiting

  • Condition:   Hepatocellular Carcinoma
    Interventions:   Genetic: GLYCAR T cells;   Drug: Cytoxan;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System
    Recruiting

  • Conditions:   Hematologic Malignancies;   Nonmalignant Diseases;   Immunodeficiencies;   Hemoglobinopathies;   Genetic Inborn Errors of Metabolism;   Fanconi Anemia;   Thalassemia;   Sickle Cell Disease
    Intervention:  
    Sponsors:   University of California, San Francisco;   Thrasher Research Fund
    Recruiting

  • Conditions:   B-Lymphoid Malignancies;   Acute Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia;   Non-hodgkin Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Biological: iC9/CAR.19/IL15-Transduced CB-NK Cells;   Drug: AP1903
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Hematopoietic/Lymphoid Cancer;   Acute Myeloid Leukemia
    Interventions:   Procedure: Leukapheresis;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: CD33-CAR-T Cell Infusion
    Sponsors:   M.D. Anderson Cancer Center;   Intrexon Corporation;   Ziopharm
    Recruiting

  • Conditions:   Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
    Interventions:   Genetic: CAR T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Peripheral Blood White Cells;   CD19 Positive;   Chronic Lymphocytic Leukemia;   Minimal Residual Disease;   Non-Hodgkin Lymphoma;   Small Lymphocytic Lymphoma
    Interventions:   Biological: Autologous CD19-CD8-CD28-CD3zeta-CAR-mbIL15-HER1t T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   M.D. Anderson Cancer Center;   Ziopharm Oncology;   Precigen, Inc
    Not yet recruiting

  • Conditions:   Cutaneous T-cell Lymphoma;   T-Prolymphocytic Leukemia;   T-Large Granulocytic Leukemia;   T-Lymphoblastic Leukemia/Lymphoma;   Peripheral T-Cell Lymphoma
    Interventions:   Drug: Romidepsin;   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Stem Cell Transplant;   Drug: Thymoglobulin
    Sponsors:   Ohio State University Comprehensive Cancer Center;   Celgene Corporation
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Immunoglobulin Heavy Chain Locus Variable Region Mutation;   Small Lymphocytic Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Graft Failure;   Secondary Graft Failure
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Hematopoietic stem cell infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Hematologic Malignancies;   Nonmalignant Diseases;   Immunodeficiencies;   Hemoglobinopathies;   Genetic Inborn Errors of Metabolism;   Fanconi's Anemia;   Thalassemia;   Sickle Cell Disease
    Intervention:  
    Sponsor:   University of California, San Francisco
    Recruiting

  • Conditions:   Hodgkin Disease;   Non-Hodgkin Lymphoma;   Severe Chronic Active Epstein Barr Virus;   T/NK-lymphoproliferative Disease
    Interventions:   Biological: MABEL CTLs;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Conditions:   Acute Myeloid Leukemia, in Relapse;   Acute Myeloid Leukemia, Adult;   Acute Myeloid Leukemia, Refractory
    Intervention:   Biological: CART123 cells; cyclophosphamide; fludarabine
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Leukemia, Lymphoid;   Leukemia, Myeloid;   Myelodysplastic Syndromes;   Myelofibrosis;   Lymphoma, Malignant;   Multiple Myeloma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Biological: Rabbit ATG;   Drug: Methotrexate
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   Fanconi Anemia;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Anti-Thymocyte Globulin (Rabbit);   Device: The CliniMACS device;   Drug: G-CSF
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Pediatric Brain Tumor Consortium
    Recruiting

  • Conditions:   Multiple Myeloma;   CLL;   Chronic Lymphocytic Leukemia;   Lymphoma
    Interventions:   Radiation: Total Body Irradiation;   Procedure: Haploidentical Stem Cell Transplantation;   Biological: CD56-Enriched Donor Lymphocyte Infusion;   Drug: Bendamustine;   Drug: Fludarabine;   Drug: Rituximab
    Sponsors:   Noah Merin;   Miltenyi Biotec GmbH;   Teva Pharmaceutical Industries
    Recruiting

  • Conditions:   HLA-A*0201 HA-1 Positive Cells Present;   Juvenile Myelomonocytic Leukemia;   Recurrent Acute Biphenotypic Leukemia;   Recurrent Acute Undifferentiated Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Chronic Myelomonocytic Leukemia;   Donor;   Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm;   Recurrent Myelodysplastic Syndrome;   Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm;   Refractory Myelodysplastic Syndrome;   Acute Undifferentiated Leukemia;   Blast Cells Present;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Minimal Residual Disease;   Mixed Phenotype Acute Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Biological: CD8+ and CD4+ Donor Memory T-cells-expressing HA1-Specific TCR;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Alex's Lemonade Stand Foundation;   National Cancer Institute (NCI);   The Leukemia and Lymphoma Society
    Recruiting

  • Conditions:   Lymphoma;   Lymphoma, B-Cell;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases
    Interventions:   Biological: iC9-CAR19 T cells;   Drug: Bendamustine;   Drug: Fludarabine;   Drug: AP1903
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Bellicum Pharmaceuticals;   V Foundation
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Hematopoietic Stem Cell Transplant (HSCT)
    Interventions:   Drug: Reduced-Intensity Conditioning Regimen;   Drug: Myeloablative Conditioning Regimen
    Sponsor:   Randy Windreich
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia, in Relapse;   Acute Lymphoblastic Leukemia, Refractory
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Mesna;   Device: CliniMACS;   Biological: CD19- specific CAR engineered autologous T-cells (SJCAR19 product)
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Osteosarcoma;   Neuroblastoma
    Interventions:   Genetic: GD2 T cells;   Biological: VZV vaccine;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   National Cancer Institute (NCI);   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital
    Recruiting

  • Conditions:   Sickle Cell Disease;   Beta Thalassemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Alemtuzumab;   Procedure: Allogeneic stem cell transplant
    Sponsor:   Columbia University
    Recruiting

  • Conditions:   Lymphoma;   Leukemia
    Interventions:   Drug: CMC-544;   Drug: Fludarabine;   Drug: Bendamustine;   Drug: Rituximab;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Thymoglobulin;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   B-cell Acute Lymphoblastic Leukemia
    Interventions:   Genetic: PBCAR0191;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Precision BioSciences, Inc.
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Immune System Diseases;   Immunoproliferative Disorders
    Interventions:   Biological: iC9-CAR19 cells;   Drug: AP1903;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Condition:   Neoplasms
    Interventions:   Genetic: NY-ESO-1ᶜ²⁵⁹T cell;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   GlaxoSmithKline
    Recruiting

  • Conditions:   Immune Deficiency Disorders;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorders;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
    Intervention:   Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: Busulfan;   Drug: Rituximab;   Drug: ATG;   Drug: Fludarabine;   Drug: Clofarabine;   Radiation: Total Body Irradiation;   Procedure: Cord Blood Transplant;   Drug: Mycofenolate mofetil;   Drug: Tacrolimus;   Drug: Filgrastim-sndz;   Drug: Melphalan;   Drug: Cyclophosphamide;   Drug: Mesna
    Sponsors:   M.D. Anderson Cancer Center;   Mesoblast, Inc.
    Recruiting

  • Conditions:   Myeloma-Multiple;   Myeloma, Plasma-Cell
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Anti-BCMA CAR T cells
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Hematologic Disorders;   Hemoglobinopathies;   Immunodeficiencies
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Radiation: Total body irradiation;   Biological: Stem cell transplant;   Drug: Keppra
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Castration Levels of Testosterone;   Castration-Resistant Prostate Carcinoma;   Metastatic Prostate Carcinoma;   PSA Progression;   Stage IV Prostate Cancer AJCC v8;   Stage IVA Prostate Cancer AJCC v8;   Stage IVB Prostate Cancer AJCC v8
    Interventions:   Biological: Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Fludarabine Phosphate
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Lymphoma, Large-Cell, Anaplasitc;   Hodgkin Disease;   Lymphoma, Hodgkins;   Enteropathy-Associated T-Cell Lymphoma;   Lymphoma, Extranodal NK-T-Cell
    Interventions:   Biological: Anti-CD30-CAR T cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Solid Tumors
    Interventions:   Procedure: Production of Genetically-modified T cells;   Drug: Cyclophosphamide;   Device: IP Catheter Insertion;   Genetic: Infusion of 4H11-28z/fIL-12/EGFRt+ Genetically-modified T cells;   Drug: Fludarabine
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Stanford University;   Juno Therapeutics, Inc.
    Recruiting

  • Conditions:   Human Papillomavirus-Related Carcinoma;   Human Papillomavirus Positive Oropharyngeal Carcinoma;   Human Papillomavirus Positive Cervical Carcinoma;   Human Papillomavirus Positive Anal Carcinoma;   Human Papillomavirus Positive Vulvar Carcinoma;   Human Papillomavirus Positive Penile Carcinoma
    Interventions:   Genetic: HPV Specific T Cells;   Drug: Cytoxan;   Drug: Fludarabine;   Biological: Nivolumab
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   The Methodist Hospital System
    Recruiting

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Biological: T-Cells;   Drug: Interleukin-2 (IL-2)
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas
    Recruiting

  • Condition:   Cerebral Adrenoleukodystrophy (CALD)
    Intervention:   Drug: Genetic
    Sponsor:   bluebird bio
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Biological: Descartes-08;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Cartesian Therapeutics
    Recruiting

  • Conditions:   Acute Lymphoid Leukemia;   B-Cell Leukemia;   Leukemia, Lymphocytic, B Cell;   B-Cell Lymphoma;   Lymphoma, Non-Hodgkin
    Interventions:   Biological: CD19/CD22 CAR T-Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Myelodysplastic Syndromes;   Leukemia, Myeloid, Acute;   Leukemia, Relapsed Adult Acute Myeloid;   Myelodysplastic Syndromes, Previously Treated
    Interventions:   Drug: CPX-351;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Rabbit Anti-Human T-Lymphocyte Globulin;   Biological: Haplo-Cord Stem Cell Transplantation
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Cancer;   Solid Tumor
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: IMA101 product;   Biological: Recombinant human interleukin-2;   Diagnostic Test: IMADetect;   Drug: Atezolizumab
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission;   Chronic Myelomonocytic Leukemia in Remission;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   Severe Aplastic Anemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Mesothelioma;   Mesothelioma, Malignant;   Mesothelioma; Pleura;   Mesotheliomas Pleural;   Mesothelioma Peritoneum;   Cholangiocarcinoma;   Cholangiocarcinoma Recurrent;   Ovarian Cancer;   Non Small Cell Lung Cancer;   Non Small Cell Lung Cancer Metastatic
    Interventions:   Drug: TC-210 T Cells;   Drug: fludarabine;   Drug: cyclophosphamide;   Biological: anti-PD1
    Sponsor:   TCR2 Therapeutics
    Recruiting

  • Conditions:   Glioblastoma;   Non-Small Cell Lung Cancer;   Ovarian Cancer;   Breast Cancer;   Gastrointestinal/Genitourinary Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Individual Patient TCR-Transduced PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-Malignant Hematologic Disorders
    Interventions:   Drug: Melphalan;   Drug: Thiotepa;   Drug: Clofarabine;   Drug: Fludarabine;   Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®);   Procedure: CliniMACS reagents
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Acute Lymphocytic Leukemia
    Interventions:   Biological: CD19 CAR T Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   Baylor College of Medicine;   Center for Cell and Gene Therapy, Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting

  • Conditions:   Post-Transplant Lymphoproliferative Disorder;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Radiation: Indium In-111 Ibritumomab Tiuxetan;   Drug: Mycophenolate Mofetil;   Other: Pharmacological Study;   Biological: Rituximab;   Radiation: Total-Body Irradiation;   Radiation: Yttrium Y-90 Ibritumomab Tiuxetan
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Melanoma;   Meningioma;   Breast Cancer;   Non-Small Cell Lung Cancer;   Hepatocellular Cancer
    Interventions:   Biological: Anti-NY ESO-1 mTCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Melphalan;   Drug: Pembrolizumab
    Sponsors:   Northside Hospital, Inc.;   Merck Sharp & Dohme Corp.
    Recruiting

  • Conditions:   Leukemia, Erythroblastic, Acute;   Myelodysplastic Syndromes
    Interventions:   Drug: 5-Azacytidine;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Alemtuzumab;   Radiation: Total Body Irradiation
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Conditions:   Pancreatic Cancer;   Gastric Cancer;   Gastrointestinal Cancer;   Colon Cancer;   Rectal Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: anti-KRAS G12V mTCR;   Drug: Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Pancreatic Cancer;   Renal Cell Cancer;   Breast Cancer;   Melanoma;   Ovarian Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: Anti-hCD70 CAR transduced PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Primary Immunodeficiency (PID);   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Inflammatory Conditions
    Interventions:   Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa
    Sponsor:   Paul Szabolcs
    Recruiting

  • Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Stem Cell Transplant;   Drug: Anti-thymocyte globulin
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Cervical Cancer;   Renal Cancer;   Urothelial Cancer;   Melanoma;   Breast Cancer
    Interventions:   Biological: Anti-MAGE-A3-DP4 TCR PBL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: high dose Aldesleukin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Procedure: CS1-CAR T Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Leukapheresis
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   Aggressive Non-Hodgkin Lymphoma;   Beta-2-Microglobulin Greater Than 3 g/mL;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Complete Remission;   Chromosome 13 Abnormality;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Lymphoblastic Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelofibrosis;   Pancytopenia;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Procedure: Double-Unit Umbilical Cord Blood Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Thiotepa
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Immunodeficiency Syndrome;   Non-Cancer Diagnosis;   Severe Aplastic Anemia
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Sirolimus;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Gastrointestinal Cancer;   Pancreatic Cancer;   Gastric Cancer;   Colon Cancer;   Rectal Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin;   Biological: anti-KRAS G12D mTCR PBL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Melanoma
    Interventions:   Drug: Cytoxan;   Drug: Mesna;   Drug: Fludarabine monophosphate;   Procedure: T cell Infusion;   Drug: IL-2;   Other: Questionnaire
    Sponsors:   M.D. Anderson Cancer Center;   National Institutes of Health (NIH);   National Cancer Institute (NCI);   Prometheus Laboratories;   Key Biologics, LLC
    Recruiting

  • Conditions:   Advanced Non-Small Cell Lung Cancer;   Squamous Cell Carcinoma;   Advanced NSCLC;   Adenosquamous Carcinoma;   Adenocarcinomas
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Crystal Mackall, MD;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Scleroderma, Systemic
    Interventions:   Biological: Peripheral Blood Stem Cells;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: Filgrastim;   Drug: Fludarabine
    Sponsor:   Northwestern University
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Crystal Mackall, MD;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Conditions:   Fanconi Anemia;   Severe Marrow Failure;   Myelodysplastic Syndrome (MDS);   Acute Myelogenous Leukemia (AML)
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: rabbit ATG;   Drug: G-CSF;   Biological: Peripheral blood stem cell
    Sponsors:   Children's Hospital Medical Center, Cincinnati;   Memorial Sloan Kettering Cancer Center;   Fred Hutchinson Cancer Research Center
    Recruiting

  • Conditions:   Acute Myeloid Leukemia (AML);   Acute Lymphocytic Leukemia (ALL);   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelofibrosis;   Myelodysplasia;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Diffuse Large B Cell Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Cyclosporine A;   Drug: Mycophenylate mofetil;   Biological: Umbilical cord blood
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Leukemia;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Diffuse Large B-Cell Lymphoma;   Follicular Lymphoma;   Graft Versus Host Disease;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes;   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   Secondary Myelodysplastic Syndrome
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Procedure: Hematopoietic Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan Hydrochloride;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Neuroblastoma
    Interventions:   Biological: iC9.GD2.CAR.IL-15 T-cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Idarubicin;   Drug: Filgrastim;   Drug: Pegylated Filgrastim;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   AbbVie
    Recruiting

  • Conditions:   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cytarabine;   Biological: Filgrastim-sndz;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   B-cell Acute Lymphoblastic Leukemia
    Interventions:   Diagnostic Test: NGS-MRD;   Drug: Myeloablative allogeneic HCT with a non-TBI conditioning regimen
    Sponsor:   Children's Hospital Los Angeles
    Recruiting

  • Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Lymphoplasmacytic Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Recurrent Transformed B-cell Non-Hodgkin Lymphoma;   Recurrent Transformed Chronic Lymphocytic Leukemia;   Refractory Marginal Zone Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma;   Refractory Transformed Chronic Lymphocytic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma;   TNFRSF17 Positive
    Interventions:   Biological: Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Juno Therapeutics, Inc.;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Chronic Myelomonocytic Leukemia;   Hodgkin Lymphoma;   Indolent Non-Hodgkin Lymphoma;   Malignant Neoplasm;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Plasma Cell Myeloma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ring Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Cytopenia With Multilineage Dysplasia and Ring Sideroblasts
    Interventions:   Drug: Fludarabine;   Radiation: Total-Body Irradiation;   Biological: T Cell-Depleted Donor Lymphocyte Infusion;   Drug: Cyclophosphamide;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Aplastic Anemia;   Bone Marrow Failure;   Immunosuppression
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Condition:   Myelofibrosis
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Radiation: Total Body Irradiation (TBI);   Procedure: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Lymphoma;   Lymphoma, Non-Hodgkin;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases;   Lymphoproliferative Disorders;   Neoplasms
    Interventions:   Biological: ATLCAR.CD30.CCR4 cells;   Biological: ALTCAR.CD30 cells;   Drug: Bendamustine;   Drug: Fludarabine
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Conditions:   Non-Small Cell Lung Cancer;   Metastatic Non-small Cell Lung Cancer;   Squamous Cell Carcinoma;   Advanced NSCLC;   Adenosquamous Carcinoma;   Adenocarcinomas
    Interventions:   Procedure: Tumor-infiltrating Lymphocytes (TIL);   Drug: Nivolumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Tumor-infiltrating Lymphocyte Therapy;   Drug: Interleukin-2 (IL2)
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   Bristol-Myers Squibb;   Prometheus Inc.;   Stand Up To Cancer;   Iovance Biotherapeutics, Inc.
    Recruiting

  • Conditions:   Adult Acute Myeloid Leukemia in Remission;   Acute Biphenotypic Leukemia;   Early Relapse of Acute Myeloid Leukemia;   Late Relapse of Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Acute Myeloid Leukemia;   Adult Acute Lymphoblastic Leukemia;   Interleukin-3 Receptor Subunit Alpha Positive;   Minimal Residual Disease;   Refractory Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
    Interventions:   Drug: cyclophosphamide;   Biological: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes;   Other: laboratory biomarker analysis;   Biological: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes;   Drug: Fludarabine Phosphate
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI);   Mustang Bio, Inc.
    Recruiting

  • Conditions:   Leukemia;   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Lenalidomide;   Drug: Fludarabine monophosphate;   Drug: Melphalan;   Procedure: NK Infusion;   Procedure: CB Infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Rituximab;   Drug: Cyclophosphamide
    Sponsors:   M.D. Anderson Cancer Center;   Celgene;   American Cancer Society, Inc.;   CLL Global Research Foundation
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Radiation: total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Melphalan;   Drug: Fludarabine;   Drug: Clofarabine;   Procedure: (CliniMACS) T-cell depleted PBSC Transplant
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Leukemia;   MDS;   Myelofibrosis;   Lymphoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: Total Body Irradiation;   Other: Hematopoietic stem cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate;   Drug: G-CSF
    Sponsor:   Rafic Farah, MD
    Recruiting

  • Conditions:   Leukemia;   Lymphoma;   Myeloma;   Myeloproliferative Diseases
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Clofarabine;   Drug: Rabbit ATG;   Radiation: Total Body Irradiation (TBI);   Procedure: Cord Blood Infusions;   Drug: Rituximab;   Drug: Cyclophosphamide;   Procedure: Natural Killer Cell Infusion;   Drug: Melphalan;   Drug: Mesna
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Cancer Prevention Research Institute of Texas
    Recruiting

  • Conditions:   Recurrent Plasma Cell Myeloma;   Refractory Plasma Cell Myeloma
    Interventions:   Biological: BCMA-specific CAR-expressing T Lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Gamma-Secretase Inhibitor LY3039478;   Other: Laboratory Biomarker Analysis;   Other: Pharmacokinetic Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Other Diseases of Blood and Blood-forming Organs;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Non-Hodgkins Lymphoma;   Hodgkins Lymphoma;   Multiple Myeloma
    Interventions:   Drug: Busulfan;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Procedure: Stem Cell Infusion;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Rituximab;   Drug: Melphalan;   Drug: Fludarabine;   Radiation: Total body irradiation (TBI);   Procedure: Stem Cell Infusion;   Drug: Cyclophosphamide;   Drug: G-CSF
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Myelodysplastic Syndrome;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Childhood Myelodysplastic Syndrome;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Bone Marrow Failure Syndrome;   Thalassemia;   Sickle Cell Disease;   Diamond Blackfan Anemia;   Acquired Neutropenia in Newborn;   Acquired Anemia Hemolytic;   Acquired Thrombocytopenia;   Hemophagocytic Lymphohistiocytoses;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Common Variable Immunodeficiency;   X-linked Lymphoproliferative Disease;   Severe Combined Immunodeficiency;   Hurler Syndrome;   Mannosidosis;   Adrenoleukodystrophy
    Interventions:   Drug: Thiotepa--single daily dose;   Drug: Thiotepa--escalated dose
    Sponsor:   University of Florida
    Recruiting

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   MYC Gene Rearrangement;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma
    Interventions:   Biological: Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Other: Laboratory Biomarker Analysis;   Procedure: Leukapheresis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Leukemia;   Myeloproliferative Diseases
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Procedure: Expanded NK Cell Infusion;   Procedure: Bone Marrow Transplant;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Radiation: Total Body Irradiation (TBI)
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas
    Recruiting

  • Conditions:   Mucopolysaccharidosis Disorders;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux Lamy Syndrome;   Sly Syndrome;   Alpha-Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Glycoprotein Metabolic Disorders;   Sphingolipidoses;   Recessive Leukodystrophies;   Globoid Cell Leukodystrophy;   Metachromatic Leukodystrophy;   Niemann-Pick B;   Niemann-Pick C Subtype 2;   Sphingomyelin Deficiency;   Peroxisomal Disorders;   Adrenoleukodystrophy With Cerebral Involvement;   Zellweger Syndrome;   Neonatal Adrenoleukodystrophy;   Infantile Refsum Disease;   Acyl-CoA Oxidase Deficiency;   D-Bifunctional Enzyme Deficiency;   Multifunctional Enzyme Deficiency;   Alpha-methylacyl-CoA Racmase Deficiency;   Mitochondrial Neurogastrointestingal Encephalopathy;   Severe Osteopetrosis;   Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation);   Inherited Metabolic Disorders
    Interventions:   Biological: Stem Cell Transplantation;   Drug: IMD Preparative Regimen;   Drug: Osteopetrosis Only Preparative Regimen;   Drug: Osteopetrosis Haploidentical Only Preparative Regimen;   Drug: cALD SR-A (Standard-Risk, Regimen A);   Drug: cALD SR-B (Standard-Risk, Regimen B);   Drug: cALD HR-D (High-Risk, Regimen C);   Drug: cALD HR-D (High-Risk, Regimen D)
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Rabbit ATG
    Sponsor:   Northside Hospital, Inc.
    Recruiting

  • Condition:   Hematologic Malignancy
    Interventions:   Drug: melphalan;   Drug: fludarabine;   Drug: thiotepa;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Mycophenolate Mofetil;   Drug: Filgrastim;   Drug: Tacrolimus
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Severe Combined Immunodeficiency
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Busulfan;   Drug: Fludarabine;   Drug: Thiotepa;   Device: CliniMACS;   Other: Donor Lymphocyte Infusion
    Sponsor:   St. Jude Children's Research Hospital
    Not yet recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myelodysplastic Syndromes (MDS);   NK-Cell Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma (NHL);   Juvenile Myelomonocytic Leukemia (JMML);   Chronic Myeloid Leukemia (CML)
    Interventions:   Drug: Cyclophosphamide;   Biological: Fludarabine;   Drug: Thiotepa;   Drug: Melphalan;   Biological: G-csf;   Drug: Mesna;   Device: CliniMACS;   Biological: ATG (rabbit);   Drug: Blinatumomab;   Biological: TCRα/β+;   Biological: CD19+;   Biological: CD45RA-depleted DLI
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Melanoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldeslaukin;   Drug: Pembrolizumab;   Biological: young TIL
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Multiple Myeloma;   Melanoma;   Synovial Sarcoma;   Myxoid/Round Cell Liposarcoma
    Interventions:   Biological: NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Device: NY-ESO-1 expression testing
    Sponsors:   University of Pennsylvania;   Parker Institute for Cancer Immunotherapy;   Tmunity Therapeutics Inc.
    Recruiting

  • Conditions:   Graft Versus Host Disease;   Hematopoietic/Lymphoid Cancer
    Interventions:   Drug: fludarabine phosphate;   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Melanoma
    Interventions:   Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T-Cells;   Biological: Interleukin-2;   Drug: Mesna;   Biological: Intrathecal T-Cells;   Biological: Intrathecal Interleukin-2
    Sponsors:   M.D. Anderson Cancer Center;   Prometheus Laboratories;   Key Biologics, LLC;   National Cancer Institute (NCI);   Adelson Medical Research
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndromes;   Myelofibrosis;   Relapsed Non-Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma;   Hodgkin Lymphoma;   Refractory Hodgkin Lymphoma;   Relapsed Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   Lymphoid Malignancies;   Chronic Myelogenous Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Procedure: mesenchymal stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Hemoglobinopathies
    Interventions:   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide (CTX);   Drug: Mesna;   Drug: Sirolimus;   Drug: Mycophenolate mofetil (MMF);   Procedure: Bone marrow transplantation;   Radiation: Total body irradiation
    Sponsor:   Vanderbilt-Ingram Cancer Center
    Recruiting

  • Conditions:   High Grade Ovarian Serous Adenocarcinoma;   Oligometastasis;   Ovarian Carcinosarcoma;   Pancreatic Ductal Adenocarcinoma;   Recurrent Osteosarcoma;   Recurrent Ovarian Carcinoma;   Refractory Osteosarcoma;   Refractory Ovarian Carcinoma
    Interventions:   Biological: Autologous Tumor Infiltrating Lymphocytes MDA-TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Interleukin-2;   Other: Quality-of-Life Assessment
    Sponsors:   M.D. Anderson Cancer Center;   Iovance Biotherapeutics, Inc.;   Bristol-Myers Squibb
    Recruiting

  • Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Plasma Cell Leukemia;   Myelodysplastic Syndromes;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   B-Cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Leukemia;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Myeloproliferative Syndromes;   Hematological Diseases
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: ATG;   Radiation: TBI;   Drug: Tacrolimus;   Drug: MMF;   Biological: Peripheral Blood Stem Cells;   Biological: Related or Unrelated Bone Marrow Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Mantle-Cell Lymphoma;   Follicular Lymphoma;   Indolent B Cell Lymphoma;   Primary Mediastinal Lymphoma;   Lymphoplasmacytic Lymphoma
    Intervention:   Biological: Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
    Interventions:   Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine phosphate 30 mg;   Drug: MESNA
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: LN-145;   Drug: IL-2;   Drug: Mesna;   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   Iovance Biotherapeutics, Inc.
    Recruiting

  • Conditions:   Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Ovarian Cancer;   Metastatic Breast Cancer
    Interventions:   Biological: Young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Pembrolizumab (Keytruda)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Combination Product: BCMA CART + huCART19;   Combination Product: CART BCMA or CART BCMA + huCART19;   Combination Product: Single-dose infusion of CART BCMA or CART BCMA + huCART19
    Sponsors:   University of Pennsylvania;   Novartis
    Recruiting

  • Conditions:   Leukemia;   Lymphoma
    Interventions:   Radiation: Total Lymphoid Irradiation;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Thiotepa;   Drug: Melphalan;   Biological: HPC,A Infusion;   Biological: TC-NK Infusion;   Biological: G-CSF;   Drug: Mesna;   Device: CliniMACS;   Drug: Mycophenolate mofetil
    Sponsors:   St. Jude Children's Research Hospital;   Assisi Foundation
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Myeloid Sarcoma;   Chronic Myeloid Leukemia (CML);   Juvenile Myelomonocytic Leukemia (JMML);   Myelodysplastic Syndrome (MDS);   Non-Hodgkin Lymphoma (NHL)
    Interventions:   Drug: Anti-thymocyte globulin (rabbit);   Drug: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: G-CSF;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Drug: Tacrolimus;   Drug: Thiotepa;   Biological: HPC,A Infusion;   Device: CliniMACS;   Drug: Sirolimus
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Mycophenolate mofetil;   Drug: Sirolimus;   Drug: Fludarabine;   Radiation: Total body irradiation;   Procedure: Hematopoietic stem cell transplant
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Myeloid Diseases
    Interventions:   Drug: Antithymocyte globulin (Rabbit);   Drug: fludarabine;   Radiation: total body irradiation;   Drug: cyclophosphamide;   Drug: Rituxan;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   B-cell Lymphoma
    Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Post-transplant Lymphoproliferative Disorder;   B-Cell Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma;   B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma;   Recurrent Lymphoplasmacytic Lymphoma
    Interventions:   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Drug: Bendamustine Hydrochloride;   Drug: Etoposide;   Drug: Fludarabine Phosphate;   Biological: Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia in Remission;   Chronic Myelomonocytic Leukemia;   Myeloproliferative Neoplasm, Unclassifiable
    Interventions:   Biological: Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total-Body Irradiation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Bone Marrow Transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Biological: Granulocyte Colony-Stimulating Factor
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Systemic Sclerosis;   Scleroderma
    Interventions:   Drug: Rituximab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: rATG;   Drug: Methylprednisolone;   Drug: G-CSF;   Biological: IVIg;   Biological: Autologous Stem Cells
    Sponsor:   Northwestern University
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Aplastic Anemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Neutrophilic Leukemia;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Mastocytosis;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Polycythemia Vera;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Ringed Sideroblasts;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine;   Drug: Busulfan;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Allogeneic hematopoietic stem cell transplantation;   Procedure: Peripheral blood stem cell transplantation (PBSCT)
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: Fludarabine phosphate;   Drug: Thiotepa;   Radiation: Total body irradiation;   Biological: Therapeutic allogeneic lymphocytes;   Drug: Cyclophosphamide;   Procedure: Allogeneic hematopoietic stem cell transplantation (HSCT);   Procedure: Peripheral blood stem cell transplantation;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Chronic Lymphocytic Leukemia;   Chronic Myeloid Leukemia;   Myelodysplasia;   Myeloproliferative Disorder;   Myelofibrosis;   Lymphoma;   Lymphoma, Non-Hodgkin;   Plasma Cell Disorder
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Drug: Tacrolimus;   Drug: cellcept;   Drug: g-csf;   Procedure: Peripheral Blood Transplant
    Sponsor:   Dartmouth-Hitchcock Medical Center
    Recruiting

  • Conditions:   HLA-A2 Positive Cells Present;   Metastatic Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Brain
    Interventions:   Biological: Aldesleukin;   Biological: Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes;   Drug: Cyclophosphamide;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis
    Sponsors:   Albert Einstein College of Medicine;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Non Malignant Diseases;   Immunodeficiencies;   Hemoglobinopathies
    Interventions:   Drug: RIC: Distal Campath;   Drug: RIC:Intermediate Campath;   Drug: RIC: Mini Busulfan
    Sponsor:   Children's Hospital of Philadelphia
    Recruiting

  • Condition:   Diffuse Intrinsic Pontine Glioma (DIPG)
    Interventions:   Biological: TTRNA-DC vaccines with GM-CSF;   Biological: TTRNA-xALT;   Drug: Cyclophosphamide + Fludarabine Lymphodepletive Conditioning;   Drug: Dose-Intensified TMZ;   Drug: Td vaccine;   Biological: Autologous Hematopoietic Stem Cells (HSC)
    Sponsors:   University of Florida;   Accelerate Brain Cancer Cure;   Lyla Nsouli Foundation
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Acute Myeloid Leukemia in Remission;   Aplastic Anemia;   Bone Marrow Failure;   Chronic Lymphocytic Leukemia;   Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Follicular Lymphoma;   Hematopoietic Cell Transplantation Recipient;   Hodgkin Lymphoma;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Neoplasm;   Near Complete Response of Multiple Myeloma or Plasma Cell Leukemia;   Non-Hodgkin Lymphoma;   Partial Response of Multiple Myeloma or Plasma Cell Leukemia;   Plasma Cell Myeloma
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Cyclophosphamide;   Biological: Cytokine-treated Veto Cells;   Drug: Fludarabine;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Chronic Myeloid Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome (MDS);   Juvenile Myelomonocytic Leukemia (JMML);   Acute Lymphoblastic Leukemia (ALL);   Lymphoma (Hodgkin's and Non-Hodgkin's)
    Interventions:   Device: CliniMACS CD34+ Reagent System;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Alemtuzumab;   Drug: Tacrolimus;   Drug: Melphalan;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Methylprednisolone
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Severe Aplastic Anemia;   Bone Marrow Failure Syndromes
    Interventions:   Procedure: Bone marrow transplant;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: TBI;   Drug: Mesna;   Drug: Tacrolimus;   Drug: Mycophenolic acid mofetil
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Condition:   Leukemia, Myeloid, Acute
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Procedure: Leukapheresis;   Biological: Cytokine-induced killer cells;   Biological: Aldesleukin;   Drug: ALT-803;   Procedure: Peripheral blood for correlative studies;   Procedure: Bone marrow for correlative studies
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Acute Lymphoid Leukemia (ALL);   Acute Myeloid Leukemia (AML);   Chronic Myeloid Leukemia (CML);   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Interventions:   Radiation: Hyperfractionated total body irradiation;   Drug: Thiotepa;   Drug: Cyclophosphamide;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Clofarabine;   Procedure: HPC(A) stem cell allograft;   Drug: Rituximab;   Device: Rabbit antithymocyte globulin
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Conditions:   Sickle Cell Disease;   Thalassemia;   High Risk Hematologic Disorders;   Cerebral Adrenoleukodystrophy;   Inherited Metabolic Disorders
    Intervention:   Procedure: Blood and Marrow Transplant
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   High Risk Myelodysplastic Syndrome;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Excess Blasts;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Pharmacological Study;   Radiation: Pretargeted Radioimmunotherapy;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Carcinoma
    Interventions:   Drug: MOv19-BBz CAR T cells;   Device: Alpha Folate Receptor expression test
    Sponsor:   University of Pennsylvania
    Recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacological Study;   Drug: Ruxolitinib Phosphate;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Anemia;   Beta-thalassemia Major;   Diamond-blackfan Anemia
    Interventions:   Biological: CD3/CD19 depleted leukocytes;   Biological: CD45RA depleted leukocytes;   Drug: Hydroxyurea;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa
    Sponsor:   Beth Carella, DO
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Large B-cell Lymphoma
    Interventions:   Drug: KYMRIAH;   Drug: YESCARTA;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Papillomavirus Infections;   Cervical Intraepithelial Neoplasia;   Carcinoma In Situ;   Vulvar Neoplasms;   Vulvar Diseases
    Interventions:   Biological: E7 TCR cells;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Leukemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Procedure: Alloreactive NK infusion;   Drug: Interleukin-2;   Procedure: Stem Cell Infusion;   Drug: G-CSF;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   M.D. Anderson Cancer Center;   Cancer Prevention Research Institute of Texas;   CML Program Project Grant
    Recruiting

  • Conditions:   Adult Solid Neoplasm;   Childhood Solid Neoplasm;   Metastatic Neoplasm
    Interventions:   Biological: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab;   Biological: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL;   Biological: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine;   Procedure: Positron Emission Tomography
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Single dose total body irradiation;   Procedure: Graft cell infusion;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: G-CSF;   Procedure: CIML NK cell infusion;   Drug: ALT-803;   Procedure: Leukapheresis
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Drug: Fludarabine;   Drug: Cytoxan;   Radiation: Total Body Irradiation;   Procedure: Allogeneic Blood or Marrow Transplant;   Procedure: Peripheral Blood Stem Cell Transplant;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus;   Drug: Tacrolimus
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Inherited Immune Deficiencies
    Interventions:   Drug: Fludarabine;   Drug: Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine;   Drug: Sirolimus or equivalent based on response;   Drug: Granulocyte Colony Stimulating Factor (G-CSF);   Other: hematopoietic progenitor cells
    Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting

  • Condition:   Metastatic Melanoma
    Intervention:   Drug: Tumor Infiltrating Lymphocytes
    Sponsor:   Yale University
    Recruiting

  • Conditions:   Idiopathic Pulmonary Fibrosis;   Emphysema or COPD
    Interventions:   Biological: CD3/CD19 negative hematopoietic stem cells;   Drug: Rituximab;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Thiotepa;   Drug: G-CSF;   Drug: Hydroxyurea
    Sponsor:   Paul Szabolcs
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: ATG;   Drug: fludarabine;   Drug: cyclophosphamide;   Radiation: Total body irradiation;   Procedure: Stem cell infusion;   Drug: Sirolimus;   Drug: mycophenolate mofetil
    Sponsor:   University of Illinois at Chicago
    Recruiting

  • Condition:   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Glycosylated Recombinant Human G-CSF AVI-014;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   AML;   MDS
    Intervention:   Biological: NKR-2
    Sponsors:   Celyad (formerly named Cardio3 BioSciences);   Novella Clinical
    Recruiting

  • Conditions:   HLA-A*0201 Positive Cells Present;   Locally Advanced Malignant Neoplasm;   NY-ESO-1 Positive;   Unresectable Malignant Neoplasm
    Interventions:   Other: 18F-FHBG;   Biological: Aldesleukin;   Drug: Busulfan;   Biological: Cellular Therapy;   Procedure: Computed Tomography;   Biological: Filgrastim;   Drug: Fludarabine;   Procedure: Leukapheresis;   Drug: Plerixafor;   Procedure: Positron Emission Tomography
    Sponsors:   Jonsson Comprehensive Cancer Center;   California Institute for Regenerative Medicine (CIRM);   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Myelodysplastic Syndrome;   Myeloproliferative Syndrome;   Rhabdomyosarcoma;   Ewing Sarcoma;   Primitive Neuroectodermal Tumor;   Osteosarcoma;   Neuroblastoma
    Interventions:   Procedure: TCRαβ+/CD19+ depleted Haploidentical HSCT;   Drug: Zoledronate
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Hematological Disease;   Immune Deficiencies;   Solid Tumors;   Myelofibrosis;   Multiple Myeloma;   Lymphoma
    Interventions:   Radiation: Total Body Irradiation 1200 cGy;   Drug: Fludarabine;   Drug: Pre-Stem Cell Infusion Cyclophosphamide;   Drug: Pre-Stem Cell Infusion Mesna;   Drug: Busulfan;   Drug: Melphalan;   Procedure: Stem Cell Infusion;   Drug: Post-Stem Cell Infusion Cyclophosphamide;   Drug: Post-Stem Cell Infusion Mesna;   Drug: Thiotepa
    Sponsor:   University of Rochester
    Recruiting

  • Condition:   Acute Myeloid Leukemia (AML)
    Interventions:   Drug: Selinexor;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: methotrexate/hydrocortisone/cytarabine
    Sponsors:   St. Jude Children's Research Hospital;   Karyopharm Therapeutics Inc
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Biphenotypic Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Donor;   Lymphoblastic Lymphoma;   Myelodysplastic Syndrome With Excess Blasts;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Drug: Thiotepa;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Hematological Malignancy;   Acute Leukemia in Remission;   Acute Lymphoblastic Leukemia in Remission;   Myelodysplastic Syndromes;   Non-Hodgkin Lymphoma;   Hodgkin Lymphoma
    Interventions:   Biological: Cord blood stem cells;   Drug: Valproic Acid;   Drug: Fludarabine;   Drug: cytoxan;   Drug: Thiotepa;   Biological: TBI
    Sponsor:   Alla Keyzner
    Recruiting

  • Condition:   Metastatic Melanoma
    Interventions:   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: Young Tumor Infiltrating Lymphocytes (Young TIL);   Drug: Pembrolizumab (Keytruda)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Device: CliniMACS® CD34 Reagent System;   Drug: Fludarabine;   Drug: Melphalan;   Drug: anti-thymocyte globulin (rabbit);   Drug: Rituximab;   Radiation: Total Body Irradiation;   Drug: Mycophenolate Mofetil;   Drug: Tacrolimus
    Sponsor:   Weill Medical College of Cornell University
    Recruiting

  • Condition:   Refractory Large B-cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Axicabtagene Ciloleucel;   Biological: Utomilumab
    Sponsors:   Kite, A Gilead Company;   Pfizer
    Recruiting

  • Conditions:   BCL2 Gene Rearrangement;   BCL6 Gene Rearrangement;   CD19 Positive;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High-Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   MYC Gene Rearrangement;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Interventions:   Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014;   Drug: Cyclophosphamide;   Biological: Durvalumab;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Fred Hutchinson Cancer Research Center;   AstraZeneca;   Juno Therapeutics, Inc.;   MedImmune LLC;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
    Interventions:   Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
    Sponsors:   Boston Children’s Hospital;   Dana-Farber Cancer Institute;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital Los Angeles;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   Baylor College of Medicine;   Children's Hospital of Philadelphia;   Memorial Sloan Kettering Cancer Center;   University of Wisconsin, Madison;   Karolinska University Hospital
    Recruiting

  • Conditions:   GATA2;   Immunodeficiency;   MDS
    Interventions:   Procedure: Allogeneic HSC;   Drug: Busulfan Test dose;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Busulfan (Busulfex);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia;   Adult Acute Myeloid Leukemia;   Adult Diffuse Large B-Cell Lymphoma;   Adult Myelodysplastic Syndrome;   Adult Non-Hodgkin Lymphoma;   Aggressive Non-Hodgkin Lymphoma;   Childhood Acute Lymphoblastic Leukemia;   Childhood Acute Myeloid Leukemia;   Childhood Diffuse Large B-Cell Lymphoma;   Childhood Myelodysplastic Syndrome;   Childhood Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Chronic Lymphocytic Leukemia in Remission;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Hematopoietic and Lymphoid Cell Neoplasm;   Mantle Cell Lymphoma;   Plasma Cell Myeloma;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Refractory Chronic Lymphocytic Leukemia;   T-Cell Prolymphocytic Leukemia;   Waldenstrom Macroglobulinemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Sirolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Busulfan;   Genetic: Hematopoietic stem cell transplantation
    Sponsor:   Sidney Kimmel Cancer Center at Thomas Jefferson University
    Recruiting

  • Conditions:   Leukemia;   Myelodysplastic Syndromes;   Childhood Acute Myeloid Leukemia in Remission;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Previously Treated Myelodysplastic Syndrome;   Secondary Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Excess Blasts;   Refractory Anemia;   De Novo Myelodysplastic Syndrome;   Childhood Myelodysplastic Syndrome
    Interventions:   Biological: filgrastim;   Drug: busulfan;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Thymoglobulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation;   Procedure: Bone marrow infusion;   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil;   Biological: Donor mesenchymal stem cell infusions;   Drug: Busulfan
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Refractory and/or Relapsed Metastatic Solid Tumors
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: low dose total body irradiation;   Drug: Melphalan;   Drug: Sirolimus
    Sponsor:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Recruiting

  • Conditions:   Acute Leukemia;   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia/Lymphoma;   Burkitt's Lymphoma;   Natural Killer Cell Malignancies;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome;   Large-cell Lymphoma;   Hodgkin Lymphoma;   Multiple Myeloma;   Relapsed Chronic Lymphocytic Leukemia;   Relapsed Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-cell Lymphoma;   Prolymphocytic Leukemia;   Bone Marrow Failure Syndromes;   Myeloproliferative Neoplasms/Myelofibrosis;   Biphenotypic/Undifferentiated/Prolymphocytic Leukemias;   MRD Positive Leukemia;   Leukemia or MDS in Aplasia;   Relapsed T-Cell Lymphoma;   Relapsed Multiple Myeloma;   Plasma Cell Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: MMF;   Drug: Sirolimus;   Radiation: TBI;   Biological: Umbilical cord blood cell infusion;   Biological: ATG
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Procedure: Bone Marrow Transplant (BMT);   Procedure: Bone Marrow Harvest (Donation);   Drug: Hydroxyurea;   Drug: Thiotepa;   Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Other: Rabbit Anti-thymocyte Globulin;   Radiation: Total Body Irradiation
    Sponsor:   Emory University
    Recruiting

  • Condition:   DOCK8 Deficiency
    Interventions:   Procedure: Reduced-intensity hematopoietic stem cell;   Drug: Fludarabine(Fludara, Berlex Laboratories);   Drug: Cyclophosphamide(CTX, Cytoxan);   Procedure: Total Body Irradiation (TBI);   Drug: Busulfan (Busulfex);   Procedure: Donor peripheral blood stem cell mobiliation and collection;   Procedure: Bone Marrow Harvest Procedure
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Mesenchymal stem cell transplantation;   Radiation: Total body irradiation;   Procedure: Bone marrow or umbilical cord blood (UCG) stem cell transplantation
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia
    Interventions:   Biological: GVAX;   Biological: Placebo Vaccine;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Beth Israel Deaconess Medical Center
    Recruiting

  • Condition:   Acute Myelogenous Leukemia
    Interventions:   Drug: Decitabine;   Drug: Vorinostat;   Drug: Filgrastim (G-CSF);   Drug: Fludarabine;   Drug: Cytarabine
    Sponsor:   Therapeutic Advances in Childhood Leukemia Consortium
    Recruiting

  • Conditions:   Hematopoietic Cell Transplantation Recipient;   Non-Malignant
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Procedure: Peripheral Blood Stem Cell Transplantation;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Drug: Treosulfan;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   medac GmbH;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Metabolic Disorders;   Hematologic, Immune, or Bone Marrow Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan;   Drug: Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan
    Sponsors:   Washington University School of Medicine;   St. Louis Children's Hospital
    Recruiting

  • Conditions:   Sickle Cell-thalassemia Disease;   Thalassemia
    Intervention:   Drug: peripheral blood stem cell graft that are CD34+ selected
    Sponsors:   Catherine Bollard;   Children's Research Institute
    Recruiting

  • Conditions:   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia-2;   High Grade Malignant Neoplasm;   Myelodysplastic Syndrome;   Myelodysplastic Syndrome With Excess Blasts-2;   Myeloid Neoplasm;   Previously Treated Myelodysplastic Syndrome;   Recurrent Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Cladribine;   Drug: Cyclosporine;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Fludarabine Phosphate;   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Mitoxantrone Hydrochloride;   Drug: Mycophenolate Mofetil;   Other: Questionnaire Administration;   Drug: Sirolimus;   Radiation: Total-Body Irradiation;   Drug: Melphalan Hydrochloride
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia in Remission;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Acute Myeloid Leukemia in Remission;   Blasts 5 Percent or Less of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Donor;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Myelofibrosis;   Myeloproliferative Neoplasm;   Recurrent Acute Myeloid Leukemia;   Recurrent Hodgkin Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Refractory Acute Myeloid Leukemia;   Therapy-Related Acute Myeloid Leukemia
    Interventions:   Biological: Anti-Thymocyte Globulin;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Primary Myelofibrosis;   Secondary Myelofibrosis
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Drug: Methotrexate;   Drug: Mycophenolate Mofetil;   Drug: Ruxolitinib;   Drug: Tacrolimus;   Radiation: Total-Body Irradiation;   Procedure: Umbilical Cord Blood Transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Aggressive Non-Hodgkin Lymphoma;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Chronic Lymphocytic Leukemia;   Loss of Chromosome 17p;   Myelodysplastic/Myeloproliferative Neoplasm;   Non-Hodgkin Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Aggressive Adult Non-Hodgkin Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hodgkin Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Non-Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: Atorvastatin Calcium;   Drug: Cyclosporine;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Drug: Mycophenolate Mofetil;   Procedure: Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Radiation: Total-Body Irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Relapsed/Refractory Chronic Lymphocytic Leukemia
    Interventions:   Biological: KTE-C19;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: Acalabrutinib;   Drug: Venetoclax;   Drug: Chemoimmunotherapy;   Drug: Obinutuzumab
    Sponsors:   Acerta Pharma BV;   AstraZeneca
    Not yet recruiting

  • Conditions:   Refractory Diffuse Large B Cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-Cell Lymphoma;   Transformed Follicular Lymphoma (TFL);   Primary Mediastinal B-cell Lymphoma (PMBCL);   High Grade B-cell Lymphoma (HGBCL)
    Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Biological: KTE-C19;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Biological: KTE-X19;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   Severe Aplastic Anemia (SAA);   Hypo-Plastic Myelodysplastic Syndrome (MDS)
    Intervention:   Procedure: haplo-identical transplantation
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Relapsed/Refractory Mantle Cell Lymphoma
    Interventions:   Biological: KTE-X19;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   Uveal Neoplasms;   Melanoma, Uveal
    Intervention:   Biological: Tumor Infiltrating Lymphocytes (TIL)
    Sponsor:   Udai Kammula
    Recruiting

  • Conditions:   Biliary Tract Cancer;   Cholangiocarcinoma;   Biliary Tract Neoplasms
    Intervention:   Biological: Tumor Infiltrating Lymphocytes (TIL)
    Sponsor:   Udai Kammula
    Recruiting

  • Condition:   Solid Tumor
    Interventions:   Drug: KITE-718;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Device: MAGE - A3/A6 Screening Test
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   Follicular Lymphoma;   Marginal Zone Lymphoma;   Indolent Non-Hodgkin Lymphoma
    Interventions:   Biological: axicabtagene ciloleucel;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Condition:   Acute Myeloid Leukemia in Children
    Interventions:   Drug: CIML NK Cell Infusion;   Procedure: CD3+ T Cell Product Infusion;   Procedure: Peripheral blood draw
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Refractory Acute Myelogenous Leukemia;   Relapsed Acute Myelogenous Leukemia
    Intervention:   Biological: FATE-NK100
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Refractory Cancer;   Recurrent Cancer;   Solid Tumor, Adult;   Cancer
    Interventions:   Biological: IMA203 Product;   Device: IMADetect
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Not yet recruiting

  • Conditions:   Solid Tumor, Adult;   Cancer;   Hepatocellular Carcinoma;   Hepatocellular Cancer;   Nonsmall Cell Lung Cancer;   Liver Cancer;   Lung Cancer
    Interventions:   Drug: IMA202 Product;   Device: IMA_Detect
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Solid Tumor;   Cancer;   Head and Neck Squamous Cell Carcinoma;   Non-small Cell Lung Cancer
    Interventions:   Biological: IMA201 Product;   Diagnostic Test: IMA_Detect;   Diagnostic Test: ACT-HLA
    Sponsors:   Immatics US, Inc.;   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Estrogen Receptor Negative;   HER2/Neu Negative;   Progesterone Receptor Negative;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage IV Breast Cancer AJCC v6 and v7;   Stage IV Non-Small Cell Lung Cancer AJCC v7;   Triple-Negative Breast Carcinoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: ROR1 CAR-specific Autologous T-Lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Multiple Myeloma;   Immune System Diseases
    Intervention:   Drug: CAR138 T Cells
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Conditions:   Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
    Intervention:   Biological: CD34 Stem Cell Selection Therapy
    Sponsor:   Diane George, MD
    Recruiting

  • Conditions:   Epithelial Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Biological: FATE-NK100;   Drug: Interleukin-2
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   B Acute Lymphoblastic Leukemia;   CD22 Positive;   Lymphocytic Neoplasm;   Lymphoma
    Interventions:   Procedure: Allogeneic Bone Marrow Transplantation;   Biological: Anti-Thymocyte Globulin;   Drug: Bendamustine;   Biological: Filgrastim-sndz;   Drug: Fludarabine;   Biological: Inotuzumab Ozogamicin;   Drug: Melphalan;   Drug: Methotrexate;   Procedure: Peripheral Blood Stem Cell Transplantation;   Biological: Rituximab;   Drug: Tacrolimus
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Biphenotypic/Undifferentiated Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplasia;   Relapsed Large Cell Lymphoma;   Mantle Cell Lymphoma;   Hodgkin Lymphoma;   Burkitt Lymphoma;   Relapsed T-Cell Lymphoma;   Lymphoplasmacytic Lymphoma
    Interventions:   Drug: Fludarabine (FLU);   Drug: Cyclophosphamide (CY);   Drug: Total Body Irradiation (TBI);   Drug: Tacrolimus (Tac);   Drug: Mycophenolate Mofetil (MMF);   Drug: Granulocyte Colony-Stimulating Factor (G-CSF);   Drug: Busulfan (BU);   Drug: Melphalan;   Drug: MGTA 456 Infusion
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Lymphoma;   Myeloma;   Leukemia
    Intervention:   Biological: Kappa CD28 T cells
    Sponsors:   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting

  • Conditions:   Fanconi Anemia;   Severe Aplastic Anemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Total Body Irradiation (TBI) (Plan 1);   Drug: Cyclophosphamide (CY) (Plan 1);   Drug: Fludarabine (FLU);   Drug: Methylprednisolone (MP);   Device: Donor mobilized PBSC infusion;   Drug: G-CSF;   Drug: Cyclophosphamide (CY) (Plan 2);   Drug: Rituximab
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Severe Sickle Cell Disease;   Bone Marrow Failure Syndromes;   Metabolic Disorders;   Immunologic Disorders;   Hemoglobinopathies;   Non-malignant Disorders
    Interventions:   Drug: RIC regimen;   Drug: GVHD prophylaxis regimen
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Condition:   Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Platinum-containing salvage chemotherapy (eg, R-ICE) followed by high dose therapy (eg, BEAM) and autologous stem cell transplant in responders.;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsor:   Kite, A Gilead Company
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Bladder Cancer;   Urinary Bladder Neoplasms
    Interventions:   Drug: 75 approved agents;   Other: COXEN
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sickle Cell Disease;   Transfusion Dependent Alpha- or Beta- Thalassemia;   Diamond Blackfan Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Glanzmann Thrombasthenia;   Severe Congenital Neutropenia;   Shwachman-Diamond Syndrome;   Non-Malignant Hematologic Disorders
    Interventions:   Drug: Reduced Toxicity Ablative Regimen;   Drug: Reduced Intensity Preparative Regimen;   Drug: Myeloablative Preparative Regimen
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin (ATG);   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI);   Procedure: Haplo HSCT;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil (MMF);   Drug: G-CSF
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Procedure: Haploidentical Bone Marrow Transplantation;   Drug: Hydroxyurea;   Drug: Rabbit-ATG;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Mesna
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network;   National Marrow Donor Program
    Recruiting

  • Conditions:   Sickle Cell Disease;   Graft Versus Host Disease
    Interventions:   Drug: Diphenhydramine;   Drug: Acetaminophen;   Drug: Methylprednisolone;   Drug: Meperidine;   Drug: Alemtuzumab;   Drug: Thymoglobulin;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Abatacept;   Procedure: Marrow infusion;   Drug: Sirolimus;   Drug: Mycophenolate Mofetil
    Sponsor:   Monica Bhatia
    Recruiting

  • Condition:   Sickle Cell Disease
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: r-ATG;   Procedure: Bone Marrow Transplant;   Drug: Tacrolimus;   Drug: Methotrexate;   Procedure: Standard of Care
    Sponsors:   Medical College of Wisconsin;   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   Dana-Farber Cancer Institute;   National Marrow Donor Program
    Recruiting

  • Conditions:   Acute Biphenotypic Leukemia;   Acute Leukemia;   Acute Leukemia of Ambiguous Lineage;   Acute Lymphoblastic Leukemia;   Acute Undifferentiated Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Blasts Under 25 Percent of Bone Marrow Nucleated Cells;   Blasts Under 5 Percent of Bone Marrow Nucleated Cells;   Mixed Phenotype Acute Leukemia;   Myelodysplastic Syndrome With Excess Blasts-1;   Myelodysplastic Syndrome With Excess Blasts-2
    Interventions:   Radiation: Total-Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (unmanipulated T cell replete BM);   Drug: Tacrolimus;   Drug: Methotrexate;   Biological: Allogeneic Hematopoietic Stem Cell Transplantation (naive T cell-depleted PBSC)
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Not yet recruiting

  • Condition:   Prostate Cancer
    Interventions:   Biological: CART T cells;   Drug: Cyclophosphamide 1g/m^2
    Sponsor:   University of Pennsylvania
    Recruiting

  • Condition:   Multiple Myeloma
    Interventions:   Biological: EGFRt/BCMA-41BBz CAR T cell;   Drug: Cyclophosphamide;   Drug: Lenalidomide.
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Juno Therapeutics, Inc.
    Recruiting

  • Condition:   Hodgkin Lymphoma
    Interventions:   Drug: Brentuximab Vedotin;   Procedure: Allogeneic Stem Cell Transplantation;   Drug: Reduced Intensity Conditioning
    Sponsors:   New York Medical College;   St. Baldrick's Foundation
    Recruiting

  • Condition:   Severe Aplastic Anemia
    Interventions:   Drug: cyclosporine;   Procedure: Matched Unrelated Donor Hematopoietic Stem Cell Transplant;   Drug: horse anti-thymocyte globulin (ATG);   Drug: rabbit anti-thymocyte globulin (ATG);   Drug: methotrexate;   Drug: fludarabine;   Drug: cyclophosphamide;   Radiation: low-dose total body irradiation (TBI);   Procedure: Immunosuppressive Therapy (IST)
    Sponsor:   Michael Pulsipher, MD
    Recruiting

  • Condition:   Hematologic Malignancies
    Interventions:   Biological: Haplo HCT <55 years old;   Biological: Haplo HCT ≥55 years old;   Drug: GVHD Prophylaxis;   Biological: Haplo HCT ≥55 and < 65 years old;   Biological: Haplo HCT ≥65 and ≤75 years old
    Sponsor:   Masonic Cancer Center, University of Minnesota
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes
    Interventions:   Drug: Azacitidine;   Drug: Decitabine;   Drug: Cytarabine;   Drug: Daunorubicin;   Drug: Etoposide;   Combination Product: ITMHA;   Drug: Idarubicin;   Drug: Fludarabine;   Drug: Mitoxantrone;   Drug: Erwinia asparaginase;   Drug: Sorafenib;   Drug: G-CSF;   Drug: Dexrazoxane;   Biological: Stem Cell Transplant
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Acute Myeloid Leukemia
    Interventions:   Drug: Uproleselan;   Drug: Placebo
    Sponsor:   GlycoMimetics Incorporated
    Recruiting

  • Conditions:   Relapsed/Refractory Diffuse Large B Cell Lymphoma;   Relapsed/Refractory Primary Mediastinal B Cell Lymphoma;   Relapsed/Refractory Transformed Follicular Lymphoma;   Relapsed/Refractory High-Grade B-Cell Lymphoma
    Intervention:   Biological: Axicabtagene Ciloleucel
    Sponsor:   Kite, A Gilead Company
    Available

  • Condition:   Multiple Myeloma
    Intervention:   Biological: JCARH125
    Sponsors:   Juno Therapeutics, Inc.;   Celgene Corporation
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Leukemia, Acute Myeloid;   Myeloid Leukemia, Acute;   Leukemia, Myeloid, Acute;   Acute Myelogenous Leukemia;   Leukemia, Acute Myelogenous;   Myelogenous Leukemia, Acute
    Interventions:   Drug: Iomab-B;   Drug: Conventional Care;   Procedure: HCT
    Sponsor:   Actinium Pharmaceuticals
    Recruiting

  • Condition:   Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
    Interventions:   Drug: Crenolanib;   Drug: Cytarabine;   Drug: Mitoxantrone;   Drug: Placebo Oral Tablet;   Drug: Fludarabine;   Drug: Idarubicin;   Drug: G-CSF
    Sponsor:   Arog Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Biological: Rituximab;   Drug: Conditioning Chemotherapy;   Drug: TMS;   Drug: FLAG;   Drug: EPOCH-F;   Procedure: Hematopoietic Stem Cell Transplant;   Drug: Palifermin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Sickle Cell Disease
    Intervention:   Drug: CD34 selected T-cell depleted allogeneic SCT
    Sponsors:   New York Medical College;   Children's Hospital & Research Center Oakland;   Medical College of Wisconsin;   Washington University School of Medicine;   Tufts Medical Center;   University of California, San Francisco;   University of California, Los Angeles;   Miltenyi Biotec GmbH;   Lurie Children's Hospital of Chicago
    Recruiting

  • Conditions:   Acute Leukemia of Ambiguous Lineage;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia;   Refractory Childhood Acute Lymphoblastic Leukemia
    Interventions:   Other: Chemosensitivity Assay;   Other: Cytology Specimen Collection Procedure;   Genetic: Gene Expression Analysis;   Genetic: Genetic Variation Analysis;   Drug: In Vitro Sensitivity-Directed Chemotherapy
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Standard of Care;   Genetic: JCAR017
    Sponsor:   Celgene
    Recruiting

  • Condition:   Synovial Sarcoma
    Intervention:   Biological: NY-ESO-1(c259)T Cells
    Sponsor:   GlaxoSmithKline
    Recruiting

  • Condition:   Myelodysplastic Syndromes
    Interventions:   Drug: FDA-approved drug or combination of drugs;   Drug: FLAG induction;   Drug: 7 + 3 induction;   Drug: Low-dose cytarabine;   Other: Supportive care alone;   Device: Computational biology simulations software
    Sponsors:   University of Florida;   Gateway for Cancer Research;   Cellworks Group Inc.
    Not yet recruiting

Login to Get Started